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Objective: With the increasing prevalence of diabetes, annual screening for diabetic retinopathy (DR) by
expert human grading of retinal images is challenging. Automated DR image assessment systems (ARIAS) may
provide clinically effective and cost-effective detection of retinopathy. We aimed to determine whether ARIAS can
be safely introduced into DR screening pathways to replace human graders.
Design: Observational measurement comparison study of human graders following a national screening
program for DR versus ARIAS.
Participants: Retinal images from 20 258 consecutive patients attending routine annual diabetic eye
screening between June 1, 2012, and November 4, 2013.
Methods: Retinal images were manually graded following a standard national protocol for DR screening and
were processed by 3 ARIAS: iGradingM, Retmarker, and EyeArt. Discrepancies between manual grades and
ARIAS results were sent to a reading center for arbitration.
Main Outcome Measures: Screening performance (sensitivity, false-positive rate) and diagnostic accuracy
(95% conﬁdence intervals of screening-performance measures) were determined. Economic analysis estimated
the cost per appropriate screening outcome.
Results: Sensitivity point estimates (95% conﬁdence intervals) of the ARIAS were as follows: EyeArt 94.7%
(94.2%e95.2%) for any retinopathy, 93.8% (92.9%e94.6%) for referable retinopathy (human graded as either
ungradable, maculopathy, preproliferative, or proliferative), 99.6% (97.0%e99.9%) for proliferative retinopathy;
Retmarker 73.0% (72.0 %e74.0%) for any retinopathy, 85.0% (83.6%e86.2%) for referable retinopathy, 97.9%
(94.9%e99.1%) for proliferative retinopathy. iGradingM classiﬁed all images as either having disease or being
ungradable. EyeArt and Retmarker saved costs compared with manual grading both as a replacement for initial
human grading and as a ﬁlter prior to primary human grading, although the latter approach was less
cost-effective.
Conclusions: Retmarker and EyeArt systems achieved acceptable sensitivity for referable retinopathy when
compared with that of human graders and had sufﬁcient speciﬁcity to make them cost-effective alternatives to
manual grading alone. ARIAS have the potential to reduce costs in developed-world health care economies and
to aid delivery of DR screening in developing or remote health care settings. Ophthalmology 2016;-:1e9 ª 2016
by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Patients with diabetes are at risk of developing retinal
microvascular complications that can cause vision loss, and
indeed, diabetes is the leading cause of incident blindness
among the working-age population. Early detection through
regular surveillance by clinical examination or grading of
retinal photographs is essential if sight-threatening retinop-
athy is to be identiﬁed in time to prevent vision loss.1e4
Annual screening of the retina is recommended but pre-
sents a huge challenge, given that the global prevalence of
diabetes was estimated to be 9% among adults in 2014.5 Theª 2016 by the American Academy of Ophthalmology
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Inc.delivery of diabetic screening will become more problematic
as the number of people with diabetic retinopathy (DR) is
expected to increase threefold in the United States by
20506,7 and to double in the developing world by 2030,
particularly in Asia, the Middle East, and Latin America.8
National screening programs for DR, including that of
the UK National Health Service Diabetic Eye Screening
Programme (NHS DESP),9 are effective; however, they are
also labor and capital intensive, requiring trained human
graders. Similar teleretinal imaging programs have been1http://dx.doi.org/10.1016/j.ophtha.2016.11.014
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Administration and elsewhere.10,11
Computer processing of medical images, including
ophthalmic images, has beneﬁted from advances in pro-
cessing power, the availability of large data sets, and new
image-processing techniques, which means many hitherto
difﬁcult challenges associated with their wider application
are now tractable. For instance, automated retinal image
analysis systems (ARIAS) allow the detection of DR
without the need for a human grader. A number of groups
have reported success in the use of their ARIAS for the
detection of DR.12e14 These systems triage those who have
sight-threatening DR or other retinal abnormalities, from
those at low risk of progression to sight-threatening reti-
nopathy. However, whereas the diagnostic accuracy of some
of these computer detection systems has been reported to be
comparable to that of expert graders, the independent val-
idity of ARIAS results and clinical applicability of different
commercially available ARIAS to “real-life” screening have
not been evaluated.
These image analysis systems are not currently autho-
rized for use in the NHS DESP, and their cost-effectiveness
is not known. Moreover, their applicability to US health care
settings is yet to be realized. There is a need for independent
validation of 1 of the ARIAS to meet the global challenge
of DR screening.
This study examines the screening performance of ARIAS
and the health economic implications of replacing human
graders with ARIAS at the UK’s National Health Service or
using an ARIAS as a ﬁlter prior to manual grading.15Methods
Study Design and Participants
Themain aim of the studywas to quantify the screening performance
and diagnostic accuracy of ARIAS, using NHS DESP manual
grading as the reference standard.15 The study design has been
previously described,15 and the protocol was published online.16
Retinal images were obtained from consecutive patients with a
diagnosis of diabetes mellitus who attended their annual visit at the
diabetes eye-screening program of the Homerton University Hos-
pital, London, between June 1, 2012, and November 4, 2013.17,18
Two photographic image ﬁelds were taken of each eye, 1
centered on the optic disc and the other on the macula, in accordance
with NHS DESP protocol.17 During the delivery of the screening
service, patients previously screened at the Homerton University
Hospital and known to be photographically ungradable underwent
slit-lamp biomicroscopy in the clinic. This was part of the routine
screening pathway set by the Homerton University Hospital.
Because these patients have no photographic images, they could not
be included in our study. Otherwise, all other patients who under-
went routine retinal photography as part of the screening program,
even if images were of poor quality or classiﬁed as ungradable by
the human graders, were included in the data set.
Research Governance approval was obtained. Images were
pseudonymized, and no change in the clinical pathway occurred.
Automated Retinal Image Analyses Systems
Automated systems for DR detection with a Conformité Europé-
enne (CE) mark obtained or applied for within 6 months of the start2of this study (July 2013) were eligible for evaluation. Three soft-
ware systems were identiﬁed from a literature search and discus-
sions with experts in the ﬁeld, and all 3 met the CE mark standards:
iGradingM (version 1.1; Medalytix/EMIS Health, Leeds, UK),19
Retmarker (version 0.8.2. 2014/02/10 by Retmarker Ltd
[formerly Critical Health], Coimbra, Portugal), and IDx-DR
(IDx, Iowa City, IA).14 IDx, Medalytix, and Critical-Health
agreed to participate in the study. IDx later withdrew, citing
commercial reasons. An additional company, Eyenuk Inc (Wood-
land Hills, CA), with software EyeArt, contacted us in 2013 to join
the study and undertook the process required to meet the CE mark
eligibility criterion.
All the automated systems are designed to identify cases of DR
that is mild nonproliferative (R1) or above. EyeArt is additionally
designed to identify cases requiring referral to ophthalmology (DR
that is ungradable or above). A test set of 2500 images also from the
Homerton screening program (but not the same patients) was pro-
vided to the vendors to optimize their ﬁle handling processes, to
address the fact that in practice, screening programs often capture
more than the 2 requisite image ﬁelds per eye and include nonretinal
images (e.g., images of crystalline lens or cataracts) that need to be
identiﬁed. During the study period ARIAS vendors had no access to
their systems and all processing was undertaken by the research team.
Reference Standards
All screening episodes were manually graded following NHS
DESP guidelines. Each ARIAS processed all screening episodes.
The study was designed not to establish the screening performance
of human graders,20e22 but to compare the automated systems with
outcomes from clinical practice. The screening performance of
each automated system was assessed using a reference standard
consisting of the ﬁnal human grade modiﬁed by arbitration, by an
internationally recognized fundus photographic reading center
(Doheny Image Reading Center, Los Angeles, CA). Arbitration
was carried out on a subset of disagreements between the ﬁnal
manual grade and the grades assigned by the ARIAS, without
knowledge of the assigned grade. All discrepancies with ﬁnal hu-
man grades for proliferative retinopathy (R3), preproliferative
retinopathy (R2), or maculopathy (M1) were sent to the reading
center for arbitration. A random sample of 1224 screening episodes
(including 6000 images) for which 2 or more systems disagreed
with the ﬁnal human grade of mild nonproliferative (R1) or no
retinopathy (R0) was also sent for arbitration.
Reader Experience
The Homerton diabetes eye-screening program has a stable grading
team of 18 full-time and part-time optometrists and nonoptometrist
graders holding appropriate accreditation for their designation
within the program. Performance against national standards is
reviewed and reported quarterly at board meetings. In addition, the
program has been quality assured externally by the NHS DESP.
Primary and secondary graders both meet minimum requisite
standards to grade retinopathy and are continuously monitored to
maintain quality assurance.23 In the current screening pathway,24 all
retinal images are reviewed by a primary grader (level 1 grader),
and any patients with mild or worse retinopathy or maculopathy
are reviewed by an additional grader (secondary grader; level 2
grader), with discrepancies between the primary and secondary
grader reviewed by an arbitration grader (level 3 grader).
Sample-size Calculations
A pilot study of 1340 patient-screening episodes revealed that the
prevalence of no retinopathy (R0), mild nonproliferative (R1;
approximately equal to Early Treatment Diabetic Retinopathy Study
Tufail et al  Retinopathy Image Assessment Software Performancelevel 20e43), maculopathy (M1), preproliferative (R2; Early Treat-
ment Diabetic Retinopathy Study level >43), and proliferative reti-
nopathy (R3)18 was 68%, 24%, 6.1%, 1.2%, and 0.5%, respectively.
One of the ARIAS (iGradingM) was compared with manual grading
as the reference standard. The sensitivity for mild nonproliferative
(R1), maculopathy (M1), preproliferative (R2), and proliferative
(R3) was 82%, 91%, 100%, and 100%, respectively, and 44% of
R0 cases were graded as disease present. The number of unique
patient-screening episodes (not repeat screens) undertaken in a 12-
month period at the Homerton University Hospital was 20 258. The
pilot data suggested that this sample size would provide sufﬁcient R3
events to estimate sensitivity with an acceptable level of precision of
95% conﬁdence intervals (CIs) for sensitivity ranging from 80% to
95% for each grade (and combination of grades) of retinopathy.15 All
manual grades of screened patientswere stored and accessed using the
Digital Healthcare OptoMize system version 3.6 (Digital Healthcare,
Cambridge, UK).
Statistical Analysis
Screening performance (sensitivity, false-positive rates) and diag-
nostic accuracy of ARIAS (95% CI of screening-performance
measures) were quantiﬁed using the ﬁnal manual grade with arbi-
tration by the reading center as the reference standard for each grade
of retinopathy, as well as combinations of grades. The diagnostic
accuracy of all screening-performance measures was deﬁned by
95% CI obtained by bootstrapping. Secondary analyses used
multivariable logistic regression to explore whether camera type and
patients’ age, gender, and ethnicity inﬂuenced the ARIAS output.
Health Economic Analysis
A decision-tree model was used to calculate the incremental cost-
effectiveness of replacing initial grading undertaken by humanFigure 1. Decision-tree model used to calculate the incremental cost-effectiven
graders (level 1 graders) with automated retinal image analysis system.graders (level 1 graders) with an ARIAS (Fig 1, Strategy 1) and of
using an ARIAS prior to manual grading (Fig 2, Strategy 2). The
decision tree was designed to reﬂect patient-screening pathways,
shown in Figures 1 and 2,25 and incorporated the screening levels
through which images were processed (levels 1, 2, and 3 human
graders) as well as grading outcomes (e.g., referral to
ophthalmology/hospital eye services or rescreening as part of the
annual screening program).
The health economic model used the following data: (1) the
probabilities associated with the likelihood of a patient image
continuing down each step of the retinopathy-grading pathway
shown in Figures 1 and 2, (2) the overall likelihood of correct
outcome classiﬁcation of each screening strategy (true positives
and true negatives correctly identiﬁed), and (3) bottom-up
costing of manual screening strategies and cost analysis of
ARIAS via interviews and analysis estimates. The model therefore
took into account the screening performance of automated systems
(sensitivity and false-positive rates), the efﬁcacy of manual
screening, the likelihood of rescreening, and referral rates to
ophthalmologists. For the ARIAS, an appropriate outcome was
deﬁned as (1) identiﬁcation of disease present by the ARIAS when
the reference human grade indicated the presence of potentially
sight-threatening retinopathy or technical failure (including grades
M1, R2, R3, and U); (2) identiﬁcation of no disease by the ARIAS
when the reference human grade indicated absence of retinopathy
or background retinopathy only (grades R0, R1; resulting in annual
rescreening).
The model focused on assessing the relative performance of
potential screening strategies and did not incorporate quality- or
time-related elements. Probability parameters were modeled on the
basis of Homerton hospital screening data for manual-grading
performance. ARIAS performance was mapped onto tentative
implementation protocols for automated screening software in the
National Health Service screening program for DR (Figs 1 and 2).ess of manual grading versus replacing initial grading undertaken by human
3
Figure 2. Decision-tree model used to calculate the incremental cost-effectiveness of manual grading versus replacing initial grading undertaken by human
graders (level 1 graders) with automated retinal image analysis system prior to manual grading.
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survey of the local study center, National Health Service
National Tariffs, hospital cost data, phone/e-mail conversations
with automated screening system manufacturers, the existing
literature, and expert opinion. All costs were standardized to UK
pounds sterling for 2013e2014 and, where appropriate, inﬂated
using the 2014 Personal Social Services Research Unit costs,
hospital and community health services pay, and prices index.26
Screening center full-time equivalent staff costs and productivity
(i.e., grading rate per hour) were used to derive unit costs per
screened patient across the entire screened population. Recurrent
costs (e.g., capital costs, periodic charges on technologies) were
discounted to reﬂect opportunity costs over the life span of in-
vestment. Medical capital equipment and hospital capital charges,
including overhead charges for utilities and ﬂoor space, were dis-
counted at 3.5% per annum over the expected lifespan of the
equipment or the ARIAS. All discounted charges were annualized
and incorporated into the model in terms of per-patient costs.
Costing results were converted into US dollar equivalents using
yearly average exchange rates for 2014 from the Internal Revenue
Service.27
Costing information regarding technological adoption was
sought directly from manufacturers, as the systems are not yet
available to the English National Health Service. This yielded
system costs for manufacturers that were framed as an estimated
cost for screening per patient image set and included similar
components in this estimate. Pricing would be contingent on the
number of patients for a given guaranteed contracted volume,
which has major price implications. Hence, the base case estimates
used reﬂect the size of the screening program for which we have
manual screening data. We present models for EyeArt and
Retmarker that incorporate cost information gathered from manu-
facturers using a universal ARIAS cost-per-image set as a base case4ﬁgure. Costing elements of automated screening included software
purchase, licensing, user training, server upgrades, and software
installation and integration.28,29 We undertook extensive deter-
ministic and threshold sensitivity analysis to examine the impact of
these pricing ﬁgures on results, because there are many un-
certainties related to costing a system that have not yet been
implemented in the health service.
Results
Figure 3 shows the degree of data completeness for manual grades.
Data from 20 258 consecutive screening episodes (102 856 images)
were included in the analysis. Data available for each episode
included a unique anonymized patient identiﬁer; episode
screening date; patient age, gender, and ethnicity; image ﬁle
names associated with each screening episode; camera type used;
retinopathy grade; maculopathy grade; and associated assessment
of image quality for each eye from the grader who assessed the
image. The median age was 60 years (range, 10e98 years), with
37% of patients >65 years of age. The main ethnic groups were
white (41%), Asian (35%), and black (20%). Table 1 shows the
ARIAS outcome classiﬁcations for EyeArt and Retmarker, using
the worst eye manual retinopathy grade reﬁned by arbitration as the
reference standard. The sensitivity (detection rates) point estimates
and 95% CIs of the ARIAS are presented in Table 2. For EyeArt,
sensitivity for any retinopathy (deﬁned as manual grades of mild
nonproliferative [R1], preproliferative [R2], proliferative [R3],
maculopathy [M1], and ungradable [U] combined) was 94.7%
(95% CI 94.2%e95.2%), 93.8% (95% CI 92.9%e94.6%) for
referable retinopathy (deﬁned as manual grades, preproliferative
Figure 3. Data extraction of patients with diabetes attending the Hom-
erton diabetic eye-screening program.
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combined), and 99.6% (95% CI 97.0%e99.9%) for proliferative
disease (R3). The corresponding results for Retmarker (Table 2)
were 73.0% (95% CI 72.0%e74.0%) for any retinopathy, 85.0%
(95% CI 83.6%e86.2%) for referable retinopathy, and 97.9%Table 1. Outcome Classiﬁcation of EyeArt and Retmarker Automate
Modiﬁed by A
Manual Grade (Worse Eye) No. of Screening Episodes (Column %)
Retinopathy grade
R0M0 12 796 (63%)
R1M0 4618 (23%)
U 427 (2%)
R1M1 1558 (8%)
R2 626 (3%)
R2M0 193 (1%)
R2M1 433 (2%)
R3 233 (1%)
R3M0 71 (0.4%)
R3M1 162 (1%)
Combination of grades
R0M0, R1M0 17 414 (86%)
U, R1M1, R2, R3 2844 (14%)
R1M0, U, R1M1, R2, R3 7462 (37%)
Total 20 258 (100%)
M0 ¼ no maculopathy; M1 ¼ maculopathy; R0 ¼ no retinopathy; R1 ¼ back
retinopathy; U ¼ ungradable images.17,18(95% CI 94.9%e99.1%) for proliferative retinopathy (R3). This
means that of 100 screening episodes with referable retinopathy,
94 would be correctly classiﬁed as disease by EyeArt and 6
would be incorrectly classiﬁed as no disease (false negatives),
whereas for Retmaker, 85 would be correctly classiﬁed as
disease and 15 would be incorrectly classiﬁed as no disease. The
false-positive rate for EyeArt was 80.1% for retinopathy graded
R0M0, meaning that of 100 screening episodes without any reti-
nopathy, 80 would be incorrectly classiﬁed as disease and the
remaining 20 would be correctly classiﬁed as no disease (speci-
ﬁcity of 20%). The corresponding false-positive rate for Retmarker
is lower, at 47.7% (speciﬁcity of 52.3%).
Unfortunately, iGradingM classiﬁed all screening episodes as
disease or ungradable; hence, although the sensitivities were
100%, the false-positive rate was also 100%. Examination of a
subset of images showed that the software was unable to process
disc-centered images. Sensitivity and false-positive rates for Eye-
Art were not affected by ethnicity, gender, or camera type, but
there was weak evidence of a marginal decline in sensitivity with
increasing patient’s age. Retmarker performance seemed to be
marginally inﬂuenced by patient’s age, ethnicity, and camera type.
Because of the performance of the iGradingM ARIAS, health
economic analysis was undertaken for EyeArt and Retmarker only.
This study explored the cost-effectiveness of EyeArt and Retmarker
ARIAS using 2 different strategies versus manual grading: replacing
initial manual grading (level 1 graders) with ARIAS (strategy 1), or
using ARIAS as a ﬁlter prior to manual grading (strategy 2).
Table 3 shows the costs of screening patients in our sample under
either strategy 1 or strategy 2 and using either EyeArt or Retmarker.
The results for both software systems were similar in that the ARIAS
were both cheaper but also less likely to correctly identify the
presence or absence of disease than the current manual grading
system. Although the misclassiﬁcation of R0 and R1 as disease
was relatively high for the ARIAS (Tables 1 and 2), the proportion of
potentially sight-threatening retinopathy correctly identiﬁed wasd Retinal Image Analysis Systems Compared with Manual Grade
rbitration
EyeArt Outcome (Row %) Retmarker Outcome (Row %)
No Disease Disease No Disease Disease
2542 (20%) 10 254 (80%) 6730 (53%) 6066 (47%)
217 (5%) 4401 (95%) 1585 (34%) 3033 (66%)
98 (23%) 329 (77%) 194 (45%) 233 (55%)
73 (5%) 1485 (95%) 207 (13%) 1351 (87%)
4 (1%) 622 (99%) 22 (4%) 604 (96%)
3 (2%) 190 (98%) 5 (3%) 188 (97%)
1 (0%) 432 (100%) 17 (4%) 416 (96%)
1 (0%) 232 (100%) 5 (2%) 228 (98%)
0 (0%) 71 (100%) 1 (1%) 70 (99%)
1 (1%) 161 (99%) 4 (2%) 158 (98%)
2759 (16%) 14 655 (84%) 8315 (48%) 9099 (52%)
176 (6%) 2668 (94%) 428 (15%) 2416 (85%)
393 (5%) 7069 (95%) 2013 (27%) 5449 (73%)
2935 17323 8743 11515
ground retinopathy; R2 ¼ preproliferative retinopathy; R3 ¼ proliferative
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Table 2. Sensitivity and False-Positive Rates (%) for EyeArt and
Retmaker Automated Retinal Image Analysis Systems Compared
with Manual Grade Modiﬁed by Arbitration
Classiﬁed by ARIAS as Disease
Present, % (95% Conﬁdence Interval)
Manual Grade
(Worse Eye) EyeArt Retmarker
Retinopathy grade
R0M0* 80.1 (79.4e80.8) 47.7 (46.5e48.3)
R1M0 95.3 (94.7e95.9) 65.7 (64.3e67.0)
U 77.0 (72.8e80.8) 54.6 (49.8e59.2)
R1M1 95.3 (94.1e96.3) 86.7 (84.9e88.3)
R2 99.4 (98.3e99.8) 96.5 (94.7e97.7)
R2M0 98.4 (95.3e99.5) 97.4 (93.9e98.9)
R2M1 99.8 (98.4e100) 96.1 (93.8e97.5)
R3 99.6 (97.0e99.9) 97.9 (94.9e99.1)
R3M0 100 98.6 (90.7e99.8)
R3M1 99.4 (95.8e99.9) 97.5 (93.6e99.1)
Combination of grades
R0M0, R1M0 84.2 (83.6e84.7) 52.2 (51.5e53.0)
U, R1M1, R2, R3 93.8 (92.9e94.6) 85.0 (83.6e86.2)
R1M0, U, R1M1,
R2, R3
94.7 (94.2e95.2) 73.0 (72.0e74.0)
M0 ¼ no maculopathy; M1 ¼ maculopathy; R0 ¼ no retinopathy; R1 ¼
background retinopathy; R2 ¼ preproliferative retinopathy; R3 ¼ prolif-
erative retinopathy; U ¼ ungradable images.17,18
*For manual grades R0M0, classiﬁed as disease present by the automated
retinal image analysis systems, the percentages correspond with false-
positive rates.
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patients screened, with 2844 cases of potentially sight-threatening
retinopathy, 2668 cases were correctly classiﬁed by EyeArt and
2416 cases by Retmarker. The proportion of these 2844 casesmissed
was therefore 6% (176 cases) for EyeArt and 15% (428 cases) for
Retmarker. Reassuringly, for the most severe retinopathy grade (R3,Table 3. Base Case Resul
Screening Strategy
and ARIAS Total Cost of Grading Incremental Cost
Appr
Outc
EyeArt
Strategy 1y
MG $795 164.60 e 19
ARIAS $693 344.48 $(101 820.13) 5
Strategy 2z
MG $795 164.60 e 19
ARIAS $675 138.67 $(63 063.91) 5
Retmarker
Strategy 1y
MG $795 164.60 19
ARIAS $627 913.75 $(167 250.85) 10
Strategy 2z
MG $795 164.60 e 19
ARIAS $658 012.58 $(137 152.07) 10
ARIAS ¼ automated diabetic retinopathy image assessment systems; ICER ¼
*If the ARIAS were more costly and more effective the ICER would be stated in
savings per appropriate outcome missed.
yStrategy 1 replaces the initial grading (level 1 grader) with ARIAS.
zIn strategy 2, ARIAS is used as a ﬁlter prior to manual grading by a level 1 gr
6proliferative retinopathy), all cases received the appropriate classi-
ﬁcation via EyeArt and 98.6% via Retmarker. Because the incre-
mental cost-effectiveness ratio (ICER) lies in the southwest quadrant
of a cost-effectiveness plane (intervention being less costly and less
effective than the status quo), we have to think carefully about
interpretation. Here, a lower ICERmeans that the intervention is less
cost-effective.30 For both Retmarker and EyeArt, strategy 1 provides
more cost savings per appropriate outcomes missed than strategy 2
does. With strategy 2, ICER results for Retmarker still lie in the
southwest quadrant. However, in comparison with strategy 1, there
would be lower cost savings per appropriate outcome missed, at
$15.36. The effectiveness measures of strategies 1 and 2 for the
same software system were nearly identical. This outcome likely
reﬂects the fact that the presence of a level 1 grader has no bearing
on the disease classiﬁcation given to patient episodes from
automated screening systems. The cost implications emerge
because patients are more likely to see more graders in strategy 2,
and level 1 grader costs per patient are higher than those of level 2
graders, reﬂecting a proportionally larger share of full-time equiva-
lents dedicated to the screening clinic. The average difference in cost
in the no disease arm between strategy 1 and strategy 2 for Retmarker
was $0.38 per patient and in the disease arm $2.33. Therefore, the
biggest cost difference comes for those patients who were more
likely to see a higher number of human graders when the automated
screening system acts as a ﬁlter rather than a replacement.
Of key importance to our ﬁndings was the cost of automated
screening. We undertook 1-way sensitivity analysis to check the
robustness of our ﬁndings to 50% changes in ARIAS pricing. When
used as a replacement for level 1 grading (strategy 1), both ARIAS
saved costs relative to manual grading but offered lower effective-
ness (appropriate identiﬁcation of disease status in patient episodes).
However, although both ARIAS are deemed less effective overall
than human graders, this was due to oversensitivity, and the ARIAS
very rarely missed any preproliferative/proliferative retinopathy or
maculopathy with mild grades of retinopathy. When used as a ﬁlter
prior to level 1 grading (strategy 2), thus reducing the volume of levelts for 20 258 Patients
opriate
omes
Incremental Appropriate
Outcomes
Cost Reduction per Appropriate
Outcome Missed (ICER)*
684 e e
427 14 257 $7.14
684 e e
428 14 256 $4.43
684
731 8953 $18.69
684 e e
760 8923 $15.36
incremental cost-effectiveness ratio; MG ¼ manual grader.
terms of cost per appropriate outcome. ICER can also be interpreted as cost
ader.
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replacement for level 1 graders. Threshold analysis testing was used
to identify the highest ARIAS cost per patient before which they
become more expensive per appropriate outcome than human
grading. For Retmarker, this ﬁgure was $6.04 under strategy 1 and
$5.19 for strategy 2. For EyeArt, ARIAS pricing above $4.29 and
$3.24 per patient would make the system more expensive than
manual grading under strategy 1 and strategy 2, respectively.Discussion
The detection of DR is a complex image-interpretation task
and a key step in any successful screening program. We
have shown that Retmarker and EyeArt ARIAS achieved
acceptable sensitivity for referable retinopathy compared
with that of human graders, at a level of speciﬁcity that
makes them cost-effective alternatives to a purely manual
grading of DR. Whereas these 2 ARIAS have good sensi-
tivity, their low speciﬁcity makes them less effective in
detecting appropriate outcomes overall than manual grading
is, but they are less expensive per patient, with these cost
results being robust to signiﬁcant variations in ARIAS
pricing. Although both ARIAS are deemed less effective
overall than human graders because of excessive sensitivity,
they rarely missed any preproliferative/proliferative reti-
nopathy or maculopathy with mild grades of retinopathy
(e.g., EyeArt picked up 95% of cases of maculopathy with
mild retinopathy [R1M1]). In light of the screening program
protocols evaluated, even if an automated screening soft-
ware is overly sensitive, the patient is likely to achieve the
appropriate outcome at the end of his or her acute episode.
This is expected to come at a total grading cost that is
cheaper regardless of whether a replacement or ﬁlter strat-
egy is chosen for implementation of the automated
screening system. For implementation into screening path-
ways, some additional technical issues have to be addressed,
including system integration, which this study showed was a
problem in a real screening environment.
This study was not designed to look at the accuracy of
human graders. In the Scottish Diabetic Retinopathy
Screening Programme, which used similar feature-based
grading with 1-ﬁeld photography and a reference standard
deﬁned as a consensus grade from the top-level graders, the
sensitivity for referable retinopathy for human graders was
found to be 91.1% on average. Sensitivity varied by center,
from 81.9% (75.2%e87.1%) to 95.0% (91.5%e97.1%).
The intergrader agreement for referable retinopathy across
all grading episodes was 88.7% (95% CI 88.0%e89.4%).31
A recent modeling study of a DR screening data set from the
United Kingdom showed an estimated 11% of cases would
have sight-threatening retinopathy missed by human
graders.32 These ﬁndings suggest that similar screening
programs using trained human graders have test
performance comparable to that of the ARIAS used.
This study, in keeping with the remit of established DR
screening programs such as the NHS DESP, was not
designed to diagnose non-DR eye disease. However,
Retmarker and EyeArt did not miss any vision-threateningnon-DR retinal conditions from the subset of images that
went to the reading center for arbitration.
As one of the ARIAS processes images using cloud-
based technology, governance issues associated with this
form of data storage need to be addressed before imple-
mentation. Health economic models may be used to evaluate
the cost-effectiveness of ARIAS under different circum-
stances, including in developing-country settings. Addi-
tional studies are also required to shed light on the
sensitivity of ARIAS software to non-DR eye disease.
The ARIAS shown to be effective in this study have the
potential to support the impending challenge of DR
screening in developed, as well as developing, countries.
China, for instance, faces the challenge of currently having
an estimated 92 million patients with diabetes,33 of which at
least 50% receive no retinopathy check.34,35 In India, even
though diabetes is projected to affect over 100 million
people by 2035,36 it may be problematic to deliver screening
even with low labor costs. Introducing ARIAS in these
settings could help scale eye-screening delivery programs
while also reducing the number of manually read images by
200 million images per year in each country, assuming all
patients were screened. If properly implemented, ARIAS
may offer the opportunity to widen provision of a needed
health service while also freeing resources for other areas in
health care. The use of ARIAS, in conjunction with the
availability of low-cost retinal digital cameras and infor-
mation technology infrastructure, may therefore help make
the prevention of diabetic-associated blindness a tractable
problem.
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